SOM Innovation Biotech European Study endorsed* by EHDN

Study aims and goal: Phase IIb, randomized, double-blind, placebo-controlled study in parallel groups assessing the efficacy and safety of two doses of SOM3355 in patients suffering from Huntington’s Disease with choreic movements.
No. of study participants and sites: This Phase IIb study aims to recruit participants from 22 sites in France, Germany, Italy, Poland, Spain, Switzerland and the UK.
For further information see the clinical trial registration.

*EHDN endorsement: The EHDN endorses protocols it finds to be of a high scientific and ethical quality. The endorsement decision is made on the basis of protocol review and discussion by the EHDN Executive Committee following recommendations from the independent EHDN Scientific and Bioethical Advisory Committee. Trial protocol endorsement should not be viewed as sponsor promotion or recruitment incitement. [EHDN endorsed studies overview]